Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;17(2):e2100320.
doi: 10.1002/biot.202100320. Epub 2021 Dec 23.

Virus inactivation at moderately low pH varies with virus and buffer properties

Affiliations

Virus inactivation at moderately low pH varies with virus and buffer properties

Pratik U Joshi et al. Biotechnol J. 2022 Feb.

Abstract

Background: Virus inactivation is a critical operation in therapeutic protein manufacturing. Low pH buffers are a widely used strategy to ensure robust enveloped virus clearance. However, the choice of model virus can give varying results in viral clearance studies. Pseudorabies virus (SuHV) or herpes simplex virus-1 (HSV-1) are frequently chosen as model viruses to demonstrate the inactivation for the herpes family.

Results: In this study, SuHV, HSV-1, and equine arteritis virus (EAV) were used to compare the inactivation susceptibility at pH 4.0 and 4°C. SuHV and HSV-1 are from the same family, and EAV was chosen as a small, enveloped virus. Glycine, acetate, and citrate buffers at pH 4.0 and varying buffer strengths were studied. The inactivation susceptibility was found to be in the order of SuHV > HSV > EAV. The buffer effectiveness was found to be in the order of citrate > acetate > glycine. The smaller virus, EAV, remained stable and infectious in all the buffer types and compositions studied.

Conclusion: The variation in inactivation susceptibility of herpes viruses indicated that SuHV and HSV cannot be interchangeably used as a virus model for inactivation studies. Smaller viruses might remain adventitiously infective at moderately low pH.

Keywords: arteritis virus; bioprocessing; enveloped virus; herpesvirus; viral clearance.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Barone, P. W., Wiebe, M. E., Leung, J. C., Hussein, I. T. M., Keumurian, F. J., Bouressa, J., Brussel, A., Chen, D., Chong, M., Dehghani, H., Gerentes, L., Gilbert, J., Gold, D., Kiss, R., Kreil, T. R., Labatut, R., Li, Y., Mullberg, J., Mallet, L., … Springs, S. L. (2020). Viral contamination in biologic manufacture and implications for emerging therapies. Nature Biotechnology, 38(5), 563-572.
    1. Johnson, S. A., Brown, M. R., Lute, S. C., & Brorson, K. A. (2017). Adapting viral safety assurance strategies to continuous processing of biological products. Biotechnology Bioeng, 114(1), 21-32.
    1. Liu, H. F., Ma, J., Winter, C., & Bayer, R. (2010). Recovery and purification process development for monoclonal antibody production. mAbs, 2(5), 480-99.
    1. Chinniah, S., Hinckley, P., & Connell-Crowley, L. (2016). Characterization of operating parameters for XMuLV inactivation by low pH treatment. Biotechnology Progress, 32(1), 89-97.
    1. Ma, J., & Roush, D. (2016). Session 1.1: Viral Clearance Using Traditional, Well-Understood Unit Operations: Low pH and Detergent Viral Inactivation. Pda Journal of Pharmaceutical Science and Technology, 70(5), 410-416.

LinkOut - more resources